Mises Wire

The FDA-Patent Pharmaceutical mess

The FDA-Patent Pharmaceutical mess

Federal Circuit Snubs Pfizer On Norvasc Rehearing discusses a recent legal dispute that involves the FDA and patents and exemplifies what a mess and waste the FDA and patent system are.

So let me summarize in plain terms: Pfizer got a patent on its hypertension drug Norvasc, and also, of course, had FDA approval. So for a while it had a monopoly. As a result of a lawsuit with Apotex, who wanted to make a generic version of Norvasc, Pfizer's patent was invalidated.

Now, because Mylan Labs already had obtained FDA approval to make the generic, as soon as the patent was invalidated, Mylan Labs ramped up plans to make a generic version of Norvasc. I.e., Apotex's suit against Pfizer resulted in Mylan being unshackled. Meantime (from what I can tell from the convoluted reports about this), Mylan sues to try to prevent Apotex from getting FDA approval. Amazing: Apotex removes Pfizer's patent monopoly, thus freeing up Mylan to sell the generic; while Mylan seeks to keep the FDA's block of Apotex in place.

Can any sane person believe either the patent or FDA system does any good at all here?

All Rights Reserved ©
What is the Mises Institute?

The Mises Institute is a non-profit organization that exists to promote teaching and research in the Austrian School of economics, individual freedom, honest history, and international peace, in the tradition of Ludwig von Mises and Murray N. Rothbard. 

Non-political, non-partisan, and non-PC, we advocate a radical shift in the intellectual climate, away from statism and toward a private property order. We believe that our foundational ideas are of permanent value, and oppose all efforts at compromise, sellout, and amalgamation of these ideas with fashionable political, cultural, and social doctrines inimical to their spirit.

Become a Member
Mises Institute